natgillin/translations-raw huggingface dataset:
At Week 4, the proportion of patients with an improvement of ≥1 versus baseline in the Patient Assessment of Constipation-Quality of Life satisfaction subscale (PAC-QOL) was 47.7% in patients treated with Resolor 2 mg compared with 20.2% in patients on placebo. 
V 4. tednu je bilo razmerje bolnikov z izboljšanjem ≥ 1 v primerjavi z izhodiščem na podlestvici vprašalnika bolnikov z zaprtjem o kakovosti življenja (PAC-QOL, Patient Assessment of Constipation-Quality of Life satisfaction subscale) 47,7 % pri bolnikih, zdravljenih z zdravilom Resolor 2 mg, v primerjavi z 20,2 % pri bolnikih, zdravljenih s placebom.
The AUC0-24h exposure ratios at the NOAEL versus human children (dosed at approximately 0.04 mg/kg daily) ranged between 21 and 71 providing adequate safety margins for the clinical dose. 
V primerjavi s otroki (ki so dobivali dnevne odmerke približno 0,04 mg/kg) so se razmerja izpostavljenosti AUC0-24h pri vrednosti NOAEL gibala med 21 in 71, kar zagotavlja ustrezno varnostno rezervo za klinični odmerek.
Excipients with known effect: Each film-coated tablet contains 142.5 mg lactose (as monohydrate). 
Pomožne snovi z znanim učinkom: ena filmsko obložena tableta vsebuje 142,5 mg laktoze (v obliki monohidrata).
Resolor contains the active substance prucalopride. 
Zdravilo Resolor vsebuje zdravilno učinkovino prukaloprid.
Furthermore, giant migrating contractions are induced by prucalopride. 
Poleg tega prukaloprid sproži velike seleče se kontrakcije.
What Resolor contains 
Kaj vsebuje zdravilo Resolor
The efficacy and safety of Resolor in patients (aged ≥18 or older) with chronic constipation, were evaluated in a 24 week multicentre, randomised, double-blind, placebo controlled study (N=361). 
Učinkovitost in varnost zdravila Resolor pri bolnikih (starih ≥18 let) s kronično zaprtostjo so ocenili v 24-tedenski multicentrični, randomizirani, dvojno slepi, s placebom nadzorovani študiji (N = 361).
The primary endpoint of the study was met: a statistically significantly higher percentage of subjects in the Resolor group (37.9%) had an average of ≥3 SCBMs/week compared with subjects in the placebo treatment group (17.7%) (p<0.0001) over the 12-week double-blind treatment period. 
Primarni cilj študije je bil izpolnjen: v 12-tedenskem dvojno slepem obdobju zdravljenja je imel statistično značilno večji odstotek preizkušancev v skupini Resolor (37,9 %) povprečno ≥ 3 SCBM/teden v primerjavi s preizkušanci v skupini, ki je prejemala placebo (17,7 %) (p < 0,0001).
Nausea, diarrhoea, abdominal pain 
Zelo pogosti navzea, diareja, bolečine v trebuhu
Resolor 2 mg film-coated tablets are pink round shaped tablets marked “PRU 2” on one side. 
Filmsko obložene 2 mg tablete Resolor so rožnate okrogle tablete z oznako „PRU 2“ na eni strani.
Similar results were observed at Week 12: 46.9% in 2 mg Resolor patients versus 19.0% in placebo patients (p<0.001 vs placebo). 
Podobne rezultate so opazili v 12. tednu: 46,9 % pri bolnikih, zdravljenih z zdravilom Resolor 2 mg, v primerjavi z 19,0 % pri bolnikih, zdravljenih s placebom (p < 0,001 v primerjavi s placebom).
Resolor contains lactose 
Zdravilo Resolor vsebuje laktozo
The other ingredients are: 
Kaj vsebuje navodilo:
- if you are on renal dialysis, - if you suffer from perforation or obstruction of the gut wall, severe inflammation of the intestinal tract, such as Crohn's disease, ulcerative colitis or toxic megacolon/megarectum. 
obstruktivni ileus, huda vnetna stanja črevesa, kot so Crohnova bolezen, ulcerativni kolitis in toksični megakolon/megarektum.
Always take this medicine exactly as described in this leaflet or as your doctor has told you. 
Pri jemanju tega zdravila natančno upoštevajte navodila v tem dokumentu ali navodila svojega zdravnika.
It is important to keep to the dose as prescribed by your doctor. 
Če ste vzeli večji odmerek zdravila Resolor, kot bi smeli Pomembno je, da jemljete odmerek, ki vam ga je predpisal vaš zdravnik.
No dose adjustment is required for patients with mild to moderate renal impairment. 
Za bolnike z blago do zmerno ledvično okvaro ni potrebna prilagoditev odmerka.
Similar results were observed at Week 12: 43.4%, 42.9%, and 31.7% respectively in 2 mg Resolor patients versus 26.9%, 27.2%, and 23.4% in placebo patients (p<0.001 vs placebo). 
Podobne rezultate so opazili v 12. tednu: 43,4 %; 42,9 % oz. 31,7 % pri bolnikih, zdravljenih z 2 mg zdravila Resolor, v primerjavi s 26,9 %; 27,2 % oz. 23,4 % pri bolnikih, zdravljenih s placebom (p < 0,001 v primerjavi s placebom).
Vertigo 
Občasni vertigo
The primary efficacy endpoint was the proportion (%) of subjects that reached normalisation of bowel movements defined as an average of three or more spontaneous, complete bowel movements (SCBM) per week over the 12-week treatment period. 
Odmerki zdravila Resolor, preučevani v vsaki od teh treh študij, so vključevali 2 mg in 4 mg enkrat na dan. Primarni opazovani dogodek učinkovitosti je bil delež (%) oseb, ki so dosegle normalizacijo odvajanja blata, opredeljen kot povprečje treh ali več spontanih popolnih odvajanj blata (SCBM - spontaneous, complete bowel movements) na teden v 12tedenskem obdobju zdravljenja.
The following side effects have been reported commonly (may affect up to 1 in 10 people): decreased appetite, dizziness, vomiting, disturbed digestion (dyspepsia), windiness, abnormal bowel sounds, tiredness. 
Pogosto so poročali o naslednjih neželenih učinkih (prizadenejo lahko največ 1 od 10 bolnikov): zmanjšan apetit, vrtoglavica, bruhanje, motena prebava (dispepsija), napenjanje, nenormalni črevesni zvoki, utrujenost.
No dose adjustment is required for patients with mild to moderate hepatic impairment. 
Za bolnike z blago do zmerno jetrno okvaro prilagoditev odmerka ni potrebna.
At week 4, the proportion of patients with an improvement of ≥1 versus baseline in the PAC-SYM abdominal, stool, and rectal symptom subscales was 41.3%, 41.6%, and 31.3% respectively in patients treated with Resolor 2 mg compared with 26.9%, 24.4% and 22.9% in patients on placebo. 
V 4. tednu je bilo razmerje bolnikov z izboljšanjem ≥ 1 v primerjavi z izhodiščem na podlestvicah vprašalnika PACSYM pri trebušnih, z odvajanjem blata povezanih in rektalnih simptomih 41,3 %; 41,6% oz. 31,3 % pri bolnikih, zdravljenih z zdravilom Resolor 2 mg, v primerjavi s 26,9 %, 24,4 % in 22,9 % pri bolnikih na placebu.
Pink, round, biconvex tablets marked “PRU 2” on one side. 
Rožnate okrogle bikonveksne tablete z oznako „PRU 2“ na eni strani.
Titanium dioxide (E171) Macrogol 
Obloga tablete hipromeloza laktoza monohidrat triacetin titanov dioksid (E171) makrogol
System/Organ Class 
Organski sistem
Resolor 1 mg film-coated tablets Resolor 2 mg film-coated tablets prucalopride 
Resolor 1 mg filmsko obložene tablete Resolor 2 mg filmsko obložene tablete prukaloprid
Iron oxide red (E172) Iron oxide yellow (E172) Indigo carmine aluminium lake (E132) 
Obloga tablete hipromeloza laktoza monohidrat triacetin titanov dioksid (E171) makrogol rdeči železov oksid (E172) rumeni železov oksid (E172) indigotin (E132)
Breast-feeding is not recommended during treatment with Resolor. 
Med zdravljenjem z zdravilom Resolor se dojenje odsvetuje.
White to off-white, round, biconvex tablets marked “PRU 1” on one side. 
Bele do belkaste okrogle bikonveksne tablete z oznako „PRU 1“ na eni strani.
Tablet coating Hypromellose Lactose monohydrate Triacetin 
Zdravilo Resolor vsebuje laktozo monohidrat.
One film-coated tablet of Resolor 1 mg contains 1 mg prucalopride (as succinate). 
Ena filmsko obložena tableta zdravila Resolor 1 mg vsebuje 1 mg prukaloprida (v obliki sukcinata).
What Resolor looks like and contents of the pack Resolor 1 mg film-coated tablets are white to off-white round shaped tablets marked “PRU 1” on one side. 
Filmsko obložene 1 mg tablete Resolor so bele do belkaste okrogle tablete z oznako „PRU 1“ na eni strani.
UNIQUE IDENTIFIER - 2D BARCODE 2D barcode carrying the unique identifier included. 
EDINSTVENA OZNAKA - DVODIMENZIONALNA ČRTNA KODA
One film-coated tablet of Resolor 2 mg contains 2 mg prucalopride (as succinate). 
Ena filmsko obložena tableta zdravila Resolor 2 mg vsebuje 2 mg prukaloprida (v obliki sukcinata).
Resolor 2 mg film-coated tablets 
Resolor 2 mg filmsko obložene tablete
Resolor 1 mg film-coated tablets. 
Resolor 1 mg filmsko obložene tablete
Palpitations 
Občasni palpitacije
At week 12, 68.3% of patients treated with 2 mg Resolor had an average increase of ≥1 SBM/week versus 37.0% of placebo patients (p<0.001 vs placebo). 
povprečno zvišanje ≥1 SBM/teden v primerjavi s 37,0 % bolnikov na placebu (p < 0,001 v primerjavi s placebom).
Rectal haemorrhage 
Občasni polakiurija
Resolor 1 mg film-coated tablets prucalopride 
Resolor 1 mg filmsko obložene tablete prukaloprid
Resolor 2 mg film-coated tablets prucalopride 
Resolor 2 mg filmsko obložene tablete prukaloprid
Each film-coated tablet contains 1 mg prucalopride (as succinate) 
Ena filmsko obložena tableta vsebuje 1 mg prukaloprida (v obliki sukcinata)
PARTICULARS TO APPEAR ON THE OUTER PACKAGING 
Izgled zdravila Resolor in vsebina pakiranja
Each film-coated tablet contains 2 mg prucalopride (as succinate). 
Ena filmsko obložena tableta vsebuje 2 mg prukaloprida (v obliki sukcinata).
Each film-coated tablet contains 2 mg prucalopride (as succinate) 
Ena filmsko obložena tableta vsebuje 2 mg prukaloprida (v obliki sukcinata)
Pollakiuria 
Plodnost
EU/1/09/581/004 (7 tablets) EU/1/09/581/006 (14 tablets) EU/1/09/581/002 (28 tablets) EU/1/09/581/008 (84 tablets) 
EU/1/09/581/004 (7 tablet) EU/1/09/581/006 (14 tablet) EU/1/09/581/002 (28 tablet) EU/1/09/581/008 (84 tablet)
Very common 
Pogosti omotica
EU/1/09/581/002 (28 tablets) EU/1/09/581/004 (7 tablets) EU/1/09/581/006 (14 tablets) EU/1/09/581/008 (84 tablets) 
EU/1/09/581/002 (28 tablet) EU/1/09/581/004 (7 tablet) EU/1/09/581/006 (14 tablet) EU/1/09/581/008 (84 tablet)
EU/1/09/581/001 (28 tablets) EU/1/09/581/003 (7 tablets) EU/1/09/581/005 (14 tablets) EU/1/09/581/007 (84 tablets) 
EU/1/09/581/001 (28 tablet) EU/1/09/581/003 (7 tablet) EU/1/09/581/005 (14 tablet) EU/1/09/581/007 (84 tablet)
How to store Resolor 
Shranjevanje zdravila Resolor
EU/1/09/581/003 (7 tablets) EU/1/09/581/005 (14 tablets) EU/1/09/581/001 (28 tablets) EU/1/09/581/007 (84 tablets) 
EU/1/09/581/003 (7 tablet) EU/1/09/581/005 (14 tablet) EU/1/09/581/001 (28 tablet) EU/1/09/581/007 (84 tablet)
Do not take Resolor: - if you are allergic to prucalopride or any of the other ingredients of this medicine (listed in section 6). 
Ne jemljite zdravila Resolor: - če ste alergični na prukaloprid ali katero koli sestavino tega zdravila (navedeno v poglavju 6), - če ste na dializi, - če imate perforacijo ali obstrukcijo črevesne stene, hudo vnetje črevesa, kot so Crohnova bolezen, ulcerativni kolitis in toksični megakolon/megarektum.
LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, APPLICANT IN THE MEMBER STATES 
DODATEK I SEZNAM IMEN, FARMACEVTSKIH OBLIK, JAKOSTI ZDRAVILA, POTI UPORABE
10 bottles Zero days 
10 vialami Nič dni.
An updated version of the Risk Management Plan will be submitted to National Competent Authorities within 3 months of the Commission Decision for this procedure, to reflect the updated information on the paediatric population as agreed by CHMP. 
Posodobljena različica načrta za obvladovanje tveganja, ki odraža posodobljene informacije glede pediatrične populacije, kot je bilo dogovorjeno s CHMP, bo predložena pristojnim nacionalnim organom v roku 3 mesecev od sklepa Evropske komisije za ta postopek.
National Competent Authorities (NCAs), coordinated by the Reference Member State where applicable, shall ensure that the following conditions are fulfilled by the Marketing Authorisation Holders (MAHs): 
Nacionalni pristojni organi, ki jih koordinira referenčna država članica, kjer je to možno, bodo zagotovili, da bodo imetniki dovoljenja za promet z zdravilom izpolnili naslednje pogoje:
Conditions of the marketing authorisations 
Pogoji dovoljenja za promet z zdravilom
The overall response rate was 14.1%. 
Skupna stopnja odziva je bila 14,1 %.
Pack of 1 vial is available in a box. 
Na voljo je pakiranje z 1 vialo v škatli.
Response (n: qualified for response) 
Odziv (n: ustrezen za odziv)
*Definition of frequency terms: Very common - ≥ 10%; Common - > 5% and < 10%. 
*Definicija pogostnosti: zelo pogosto (> 10 %); pogosto (> 5 % in < 10 %).
ITT population and histology subgroups 
Populacija NZ in histološke podskupine
This is equivalent to 2.7% of the recommended maximum daily dietary intake of sodium for an adult. 
To je enako 2,7 % priporočenega največjega dnevnega vnosa natrija s hrano za odrasle osebe.
*p-value refers to comparison between arms. 
*Vrednost p se nanaša na primerjavo med vejama zdravljenja.
If you are pregnant, think you may be pregnant or are planning to have a baby, tell your doctor. 
Če ste noseči, menite, da bi lahko bili noseči, ali načrtujete zanositev, se posvetujte z zdravnikom.
Based on the planned date of your infusion of Pemetrexed Krka and/or on the status of your kidney function, your doctor needs to advise you on which medicines you can take and when you can take them. 
Na podlagi načrtovanega datuma vaše infuzije zdravila Pemetreksed Krka in/ali glede na delovanje vaših ledvic vam mora zdravnik svetovati, katera zdravila lahko jemljete in kdaj jih lahko jemljete.
Each box contains one vial. 
V vsaki škatli je ena viala.
Randomised and treated patients 
Randomizirani in zdravljeni bolniki
Frequency estimate: - Very common (1/10) - Common (1/100 to <1/10) - Uncommon (1/1,000 to <1/100) - Rare (1/10,000 to <1/1,000) - Very rare (<1/10,000) - Not known (cannot be estimated from the available data) 
Ocena pogostnosti: - zelo pogosti (≥ 1/10), - pogosti (≥ 1/100 do < 1/10), - občasni (≥ 1/1.000 do < 1/100), - redki (≥ 1/10.000 do < 1/1.000), - zelo redki (< 1/10.000), - neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
The reporting rates shown are according to CTCAE version 3.0. 
Prikazana pogostnost navedb je skladna s CTCAE (verzija 3.0).
The European Medicines Agency has waived the obligation to submit the results of studies with pemetrexed in all subsets of the paediatric population in the granted indications (see section 4.2). 
Evropska agencija za zdravila je odstopila od obveze za predložitev rezultatov študij z zdravilom Pemetreksed Krka za vse skupine pediatrične populacije za odobrene indikacije (glejte poglavje 4.2).
The total bilirubin should be ≤ 1.5-times upper limit of normal. 
Celotni bilirubin mora biti  1,5-kratnik zgornje meje normalnih vrednosti.
*p-values < 0.05 comparing pemetrexed/cisplatin to gemcitabine/cisplatin, using Fisher Exact test. 
*Vrednosti p < 0,05 pri primerjavi pemetrekseda/cisplatina in gemcitabina/cisplatina z uporabo Fisherjevega natančnega testa (Fisher Exact test).
Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; CTCAE = Common Terminology Criteria for Adverse Event; NCI = National Cancer Institute; SGOT = serum glutamic oxaloacetic aminotransferase; SGPT = serum glutamic pyruvic aminotransferase. 
Okrajšave: ALT = alaninska aminotransferaza; AST = aspartatna aminotransferaza; CTCAE = skupna merila za terminologijo neželenih učinkov (Common Terminology Criteria for Adverse Events); NCI = Nacionalni inštitut za rakava obolenja; SGOT = serumska glutamat oksalocetna aminotransferaza; SGPT = serumska glutamat piruvična aminotransferaza.
Do not use Pemetrexed Krka - if you are allergic to pemetrexed or any of the other ingredients of this medicine (listed in section 6). 
Ne uporabljajte zdravila Pemetreksed Krka: - če ste alergični na pemetreksed ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Date of first authorisation: 22. 
Datum prve odobritve: 22. maj 2018
There are no data from the use of pemetrexed in pregnant women but pemetrexed, like other antimetabolites, is suspected to cause serious birth defects when administered during pregnancy. 
Podatkov o uporabi pemetrekseda pri nosečnicah ni, a za pemetreksed, kot za druge anti-metabolite, sumimo, da povzroča resne prirojene okvare, če ga dajemo med nosečnostjo.
KRKA Farmacêutica, Sociedade Unipessoal Lda. 
Portugal KRKA Farmacêutica, Sociedade Unipessoal Lda.
Driving and using machines Pemetrexed Krka may make you feel tired. 
Vpliv na sposobnost upravljanja vozil in strojev Zdravilo Pemetreksed Krka lahko povzroči, da se boste počutili utrujene.
Calculate the dose and the number of Pemetrexed Krka vials needed. 
Izračunajte odmerek in število potrebnih vial zdravila Pemetreksed Krka.
Pemetrexed + Cisplatin Gemcitabine + Cisplatin 
Pemetreksed + cisplatin Gemcitabin + cisplatin
** which is derived from the term “renal/genitourinary other”. 
**Izhaja iz izraza “ledvice/sečila drugo”.
Alkaline phosphatase (AP), aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) should be ≤ 3-times upper limit of normal. 
Alkalna fosfataza (AF), aspartatna aminotransferaza (AST ali SGOT) in alaninska aminotransferaza (ALT ali SGPT) morajo biti  3-kratnik zgornje meje normalnih vrednosti.
See section 2 "Pemetrexed Krka contains sodium". 
Glejte poglavje 2 "Zdravilo Pemetreksed Krka vsebuje natrij".
Your doctor will discuss with you the potential risk of taking Pemetrexed Krka during pregnancy. 
Z zdravnikom se pogovorite o možnem tveganju pri prejemanju zdravila Pemetreksed Krka v času nosečnosti.
Patients must also receive an intramuscular injection of vitamin B12 (1,000 micrograms) in the week preceding the first dose of pemetrexed and once every three cycles thereafter. 
Bolniki morajo prejeti tudi intramuskularno injekcijo vitamina B12 (1.000 mikrogramov) v tednu pred prvim odmerkom pemetrekseda in enkrat vsake tri cikle zatem.
75% of previous dose 
75 % predhodnega odmerka 75 % predhodnega odmerka
Before each infusion you will have samples of your blood taken to evaluate if you have sufficient kidney and liver function and to check that you have enough blood cells to receive Pemetrexed Krka. 
Pred vsako infuzijo vam bomo odvzeli vzorce krvi za vrednotenje delovanja vaših ledvic in jeter ter oceno, ali imate dovolj krvnih celic za prejemanje zdravila Pemetreksed Krka.
Of the randomised patients, 44.9% had a complete/partial response and 51.9% had a response of stable disease to pemetrexed plus cisplatin induction. 
Izmed naključno izbranih bolnikov jih je 44,9 % doseglo popoln/delen odziv in 51,9 % jih je doseglo odziv stabilne bolezni na pemtreksed in indukcijsko zdravilo cisplatina.
Pharmacotherapeutic group: antineoplastic agents, folic acid analogues, ATC code: L01BA04. 
Farmakoterapevtska skupina: zdravila z delovanjem na novotvorbe (citostatiki), analogi folne kisline, oznaka ATC: L01BA04.
Sensitivity analyses of main efficacy endpoints were also assessed on the Protocol Qualified (PQ) population. 
Analiza primarne učinkovitosti je bila osnovana na populaciji NZ. Analize občutljivosti glavnih končnih točk učinkovitosti so ocenili tudi pri s protokolom kvalificirani (PK) populaciji.
At the time of this final survival analysis, 28.7% of patients were alive or lost to follow up on the pemetrexed arm versus 21.7% on the placebo arm. 
V času te končne analize preživetja je bilo živih ali ni bilo na voljo za nadaljnje spremljanje 28,7 % bolnikov v kraku s pemetreksedom v primerjavi z 21,7 % v kraku s placebom.
Upon recovery, patients should be re-treated using the guidelines in Tables 1, 2, and 3, which are applicable for Pemetrexed Krka used as a single agent or in combination with cisplatin. 
Po okrevanju bolnike ponovno zdravimo z uporabo smernic v Preglednicah 1, 2 in 3, ki veljajo za zdravilo Pemetreksed Krka, če jo uporabljamo kot edino učinkovino ali v kombinaciji s cisplatinom.
Chemical and physical in-use stability of reconstituted and infusion solutions of pemetrexed were demonstrated for 24 hours at 2°C to 8°C (and 25°C). 
Po pripravi je kemijska in fizikalna uporabnost rekonstituiranih raztopin pemetrekseda in raztopin pemetrekseda za infundiranje 24 ur pri temperaturi 2 °C do 8 °C (in 25 °C).
**In the pemetrexed/cisplatin arm, randomized and treated (N=225) and fully supplemented (N=167). 
**V veji zdravljenja s pemetreksidom/cisplatinom, randomizirani in zdravljeni (N = 225) ter s popolnim dopolnjevanjem (N = 167).
The dose of Pemetrexed Krka is 500 milligrams for every square metre of your body's surface area. 
Odmerek zdravila Pemetreksed Krka je 500 miligramov za vsak kvadratni meter površine vašega telesa.
Before the start of any cycle of chemotherapy, patients are required to have the following: absolute neutrophil count (ANC) should be ≥ 1500 cells/mm 
Pred začetkom kateregakoli cikla kemoterapije morajo bolniki izpolnjevati naslednja merila: absolutno število nevtrofilcev (ANC) mora biti  1500 celic/mm
****Combined term includes increased serum/blood creatinine, decreased glomerular filtration rate, renal failure and renal/genitourinary- other. 
****Skupni izraz vključuje povišan kreatinin v serumu/krvi, znižano stopnjo glomerulne filtracije, ledvično odpoved in ledvice/sečila - drugo.
a Statistically significant for non-inferiority, with the entire confidence interval for HR well below the 1.17645 non-inferiority margin (p < 0.001). 
Statistično pomembna za prednost, s celotnim intervalom zaupanja za RT znatno pod mejo prednosti 1,17645 (p < 0,001).
What Pemetrexed Krka is and what it is used for 
Kaj je zdravilo Pemetreksed Krka in za kaj ga uporabljamo
You will always receive Pemetrexed Krka by infusion into one of your veins. 
Zdravilo Pemetreksed Krka boste vedno prejeli v obliki infuzije v veno.
If you currently have or have previously had problems with your kidneys, talk to your doctor or hospital pharmacist as you may not be able to receive Pemetrexed Krka. 
Če imate ali ste imeli težave z ledvicami, se pogovorite z zdravnikom ali bolnišničnim farmacevtom, ker morda ne boste mogli prejeti zdravila Pemetreksed Krka.
If you have an accumulation of fluid around your lungs, your doctor may decide to remove the fluid before giving you Pemetrexed Krka. 
Če se vam okrog pljuč nabira tekočina, se bo zdravnik morda odločil tekočino pred dajanjem zdravila Pemetreksed Krka odstraniti.
A significant increase in the incidence of possibly study-drug-related Grade 3/4 neutropenia was observed with longer exposure to pemetrexed (≤6 cycles: 3.3%, >6 cycles: 6.4%: p=0.046). 
Znatno povečanje pojavnosti nevtropenije stopnje 3/4, ki je lahko povezano s preučevanim zdravilom, so opazili pri dolgotrajnejši izpostavljenosti pemetreksedu (≤ 6 ciklov: 3,3 %, > 6 ciklov: 6,4 %: p = 0,046).
All patients included in this study had an ECOG performance status 0 or 1. 
Vsi bolniki, vključeni v to študijo, so imeli stanje zmogljivosti po ECOG 0 ali 1.
You must contact your doctor immediately if you notice any of the following: - Fever or infection (common): if you have a temperature of 38°C or greater, sweating or other signs of infection (since you might have less white blood cells than normal which is very common). 
Če opazite katerega od spodaj naštetih učinkov, morate nemudoma poklicati zdravnika: - Povišana telesna temperatura ali okužba (pogosto): če se pojavi temperatura 38 ºC ali višja, znojenje ali drugi znaki okužbe (ker imate lahko manj belih krvničk kot normalno, kar je zelo pogosto).
It is a white to either light yellow or green yellow lyophilized cake or powder. 
Je bela do bodisi svetlo rumena ali zeleno rumena liofilizirana pogača ali prašek.
If you have been recently vaccinated, please tell your doctor, as this can possibly cause bad effects with Pemetrexed Krka. 
Če ste bili nedavno cepljeni, prosimo, povejte to zdravniku saj lahko to ob jemanju zdravila Pemetreksed Krka povzroča škodljive učinke.
What Pemetrexed Krka is and what it is used for What you need to know before you use Pemetrexed Krka How to use Pemetrexed Krka Possible side effects 
Kaj je zdravilo Pemetreksed Krka in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Pemetreksed Krka Kako uporabljati zdravilo Pemetreksed Krka Možni neželeni učinki
Frequency Event* 
Pogostnost Dogodek*